Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
OBJECTIVE
This study investigated the effect of the 102-T/C polymorphism in the 5-HT(2A) receptor gene on risperidone efficacy.


METHODS
One hundred Han Chinese patients with acutely exacerbated schizophrenia were given risperidone for up to 42 days. The patients were genotyped for 5-HT(2A) polymorphisms. Psychopathology was measured biweekly with the Positive and Negative Syndrome Scale while the patients were taking risperidone. Generalized estimating equation methods were used to analyze the effects of treatment duration, T/C genotypes, and other prognostic factors on Positive and Negative Syndrome Scale performance.


RESULTS
Patients with the C/C genotype had lower total scores, negative subscale scores, and general psychopathology scores but not positive subscale scores on the Positive and Negative Syndrome Scale than patients with the 102-T/C genotype. Patients with the T/C and T/T genotypes had comparable total and subscale scores. The number of previous hospitalizations and the dose of risperidone also affected Positive and Negative Syndrome Scale total scores.


CONCLUSIONS
These results suggest that variations in the 5-HT(2A) receptor gene may influence individual responses to risperidone.
Lane
Hsien-Yuan
HY
Department of Psychiatry, Tzu-Chi General Hospital, Institute of Neuroscience, Tzu-Chi University, Hualien City, Taiwan.
Chang
Yue-Cune
YC
Chiu
Chih-Chiang
CC
Chen
Mao-Liang
ML
Hsieh
Min-Hua
MH
Chang
Wen-Ho
WH
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin / Q000187:drug effects / Q000235:genetics*; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin; D018967:Risperidone